Rheumatoid Arthritis Completed Phase Trials for Abatacept (DB01281)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01555879Real-world Clinical Efficacy of Abatacept in the T3 Data Registry
NCT03496831Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
NCT02037737Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
NCT01583244Korean Post-marketing Surveillance for Orencia®
NCT02169544Post-marketing Study Assessing the Long-Term Safety of Abatacept
NCT02109666Long Term Experience With Abatacept in Routine Clinical Practice
NCT02598466Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa
NCT02600455Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL
NCT02600468Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg
NCT01339481A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept